Sunitinib for advanced renal cell cancer

Figures & data

Figure 1 Kaplan – Meier estimates of progression-free survival (independent central review). Reproduced with permission from Motzer RJ, Hutson TE, Tomczak P, et al 2007a. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356:115–24. Copyright © 2007 Massachusets Medical Society. All rights reserved.

Table 1 Sunitinib toxicity monitoring checklist

Potential problem	Action required
Subjective toxicities	Self-reporting, symptom management
Anorexia, taste change	Weigh each cycle (6 weeks)
Hypertension	Measure and record every 2 weeks
Cytopenias	Complete blood count each cycle
Hypothyroidism	TSH baseline and 3-monthly
Cardiac history or symptoms	ECG, cardiac ejection fraction
Tumor breakthrough weeks off	Consider continuous 37.5 mg/day
Disease progression	Measure disease each cycle initially

MotzerRJHutsonTETomczakP2007aSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med3561152417215529

 PubMed Web of Science ®Google Scholar